- Home
- DNP vs CRNX Comparison
DNP vs CRNX Comparison
Compare DNP & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$47.20
Company Overview
Basic Information| Metric | DNP | CRNX |
|---|---|---|
| Founded | 1986 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.1B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | DNP | CRNX |
|---|---|---|
| Price | $10.09 | $47.20 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $71.00 |
| AVG Volume (30 Days) | 479.6K | ★ 992.2K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 7.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.30 | N/A |
| Revenue | ★ $154,887,179.00 | $1,535,000.00 |
| Revenue This Year | N/A | $425.41 |
| Revenue Next Year | N/A | $943.30 |
| P/E Ratio | $4.26 | ★ N/A |
| Revenue Growth | 3.30 | ★ 47.74 |
| 52 Week Low | $8.69 | $24.10 |
| 52 Week High | $10.04 | $54.18 |
Technical Indicators
Market Signals| Indicator | DNP | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 54.32 | 52.35 |
| Support Level | $9.89 | $43.04 |
| Resistance Level | $10.11 | $49.61 |
| Average True Range (ATR) | 0.08 | 1.94 |
| MACD | 0.01 | -0.24 |
| Stochastic Oscillator | 95.45 | 55.10 |
Price Performance
Historical Comparison DNP
CRNX
About DNP DNP Select Income Fund Inc.
DNP Select Income Fund Inc is a closed-ended investment management fund. The primary investment objectives of the fund are current income and long-term growth of income. Its secondary objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing in the public utility industry.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.